No Data
Insiders At Vera Therapeutics Sold US$1.0m In Stock, Alluding To Potential Weakness
Vera Therapeutics Grants Stock Options And RSUs To Six New Employees
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Vera Therapeutics: Strategic Licensing and Promising Clinical Data Justify Buy Rating
Express News | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $75